All In Biotech

NDA 213702 · Jazz

Zepzelca

Lurbinectedin · Intravenous · Alkylating Drug

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jun 15, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

65

12 Phase 3, 19 recruiting

FAERS reports

1,169

937 serious, 286 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 30, 2026.

ZEPZELCA is an alkylating drug indicated: • in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, for the maintenance treatment of adult patients with extensive-stage small cell lung cancer whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide. ( 1.1 ) 1.1 Extensive-Stage Small Cell Lung Cancer ZEPZELCA, in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin and etoposide.

Mechanism: Lurbinectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death. Lurbinectedin inhibited human monocyte activity in vitro and reduced macrophage infiltration in implanted tumors in mice.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 2, 2025 Supplement 11 · Efficacy · priority review OrphanLabelLetter
  • Jun 15, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
  • ZEPZELCA · LURBINECTEDIN 4MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lurbinectedin" as an intervention, any sponsor and status, largest first.

All 65 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death150
  • disease progression108
  • neutropenia82
  • off label use82
  • nausea70
  • thrombocytopenia60
  • fatigue56
  • febrile neutropenia47
  • anaemia45
  • asthenia45
  • vomiting43
  • injection site reaction36

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20162
20171
20181
202054
2021126
2022244
2023249
2024180
2025161
2026150

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zepzelca (Lurbinectedin)

2024 spending

$2.6M

Beneficiaries

43

169 claims

Per beneficiary

$59,767

$7,907.59 per unit

View as table
YearSpending
2020$371,639
2021$1,211,475
2022$1,637,629
2023$2,435,684
2024$2,569,967

Part B: Zepzelca (Lurbinectedin) · HCPCS J9223

2024 spending

$115M

Beneficiaries

1,956

7,712 claims

Per beneficiary

$58,764

2024 ASP limit $201.47 per unit

View as table
YearSpending
2020$0
2021$88,260,768
2022$91,837,313
2023$105,340,083
2024$114,942,756

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Jazz Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.